Autoimmunity in the immune privileged eye: pathogenic and regulatory T cells, Immunologic Research, vol.237, issue.1-3, pp.41-50, 2008. ,
DOI : 10.4049/jimmunol.180.10.6751
NUSSENBLATT : A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens, J Immunol, issue.5, pp.1401490-1495, 1988. ,
Interphotoreceptor retinoid-binding protein. Gene characterization, protein repeat structure, and its evolution, J Biol Chem, vol.264, issue.2, pp.1115-1123, 1989. ,
CASPI : Rodent models of experimental autoimmune uveitis, Methods Mol Med, vol.102, pp.395-419, 2004. ,
WILDER : T cell mechanisms in experimental autoimmune uveoretinitis : susceptibility is a function of the cytokine response profile, Eye (Lond), issue.2, pp.11209-212, 1997. ,
Uveitogenicity Is Associated with a Th1-like Lymphokine Profile: Cytokine-Dependent Modulation of Early and Committed Effector T Cells in Experimental Autoimmune Uveitis, Cellular Immunology, vol.178, issue.1, pp.69-78, 1997. ,
DOI : 10.1006/cimm.1997.1121
Autoimmunity to a pathogenic retinal antigen begins as a balanced cytokine response that polarizes towards type 1 in a disease-susceptible and towards type 2 in a disease-resistant genotype, International Immunology, vol.11, issue.8, pp.111307-1312, 1999. ,
DOI : 10.1002/eji.1830270623
CASPI : IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response, J Immunol, issue.12, pp.1585997-6005, 1997. ,
Altered chemokine profile associated with exacerbated autoimmune pathology under conditions of genetic interferon-gamma deficiency, Invest Ophthalmol Vis Sci, issue.10, pp.484616-4625, 2007. ,
The IL-23/Th17 axis: therapeutic targets for autoimmune inflammation, Current Opinion in Immunology, vol.18, issue.6, pp.670-675, 2006. ,
DOI : 10.1016/j.coi.2006.09.008
Unregulated IL-23/IL-17 immune response in autoimmune diseases, Diabetes Research and Clinical Practice, vol.88, issue.3, pp.222-226, 2010. ,
DOI : 10.1016/j.diabres.2010.03.014
Interleukin-17-producing T cells in lupus, Current Opinion in Rheumatology, vol.22, issue.5, pp.499-503, 2010. ,
DOI : 10.1097/BOR.0b013e32833c62b0
Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category, The Journal of Experimental Medicine, vol.36, issue.4, pp.799-810, 2008. ,
DOI : 10.1016/0896-8411(90)90144-H
Key role for IL-21 in experimental autoimmune uveitis, Proceedings of the National Academy of Sciences, vol.101, issue.48, pp.9542-9547, 2011. ,
DOI : 10.1073/pnas.0407752101
New perspectives on effector mechanisms in uveitis, Seminars in Immunopathology, vol.204, issue.2, pp.135-143, 2008. ,
DOI : 10.4049/jimmunol.172.11.7169
Upregulated IL-23 and IL-17 in Behc??et Patients with Active Uveitis, Investigative Opthalmology & Visual Science, vol.49, issue.7, pp.3058-3064, 2008. ,
DOI : 10.1167/iovs.07-1390
Elevated serum IL-23 correlates with intraocular inflammation after cataract surgery in patients with Vogt-Koyanagi-Harada disease, British Journal of Ophthalmology, vol.94, issue.8, pp.941078-1082, 2010. ,
DOI : 10.1136/bjo.2009.169052
Intraocular Interleukin-17 and Proinflammatory Cytokines in HLA-A29???Associated Birdshot Chorioretinopathy, American Journal of Ophthalmology, vol.152, issue.2, 2011. ,
DOI : 10.1016/j.ajo.2011.01.031
MARKOMICHELAKIS : Effect of infliximab on sight-threatening panuveitis in Behçet's disease, Lancet, issue.9278, pp.358295-296, 2001. ,
Etanercept treatment in the endotoxin-induced uveitis of rats ,
Neutralizing Tumor Necrosis Factor Activity Leads to Remission in PatientsWith Refractory Noninfectious Posterior Uveitis, Archives of Ophthalmology, vol.122, issue.6, pp.845-851, 2004. ,
DOI : 10.1001/archopht.122.6.845
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia, N Engl J Med, vol.346, issue.9, pp.645-652, 2002. ,
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.115-124, 2007. ,
DOI : 10.1056/NEJMoa065044
Immunomodulatory effects of anti-angiogenic drugs, Leukemia, vol.29, issue.6, pp.899-905, 2011. ,
DOI : 10.1038/nm1763
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice, Proceedings of the National Academy of Sciences, vol.145, issue.2, pp.10518895-18900, 2008. ,
DOI : 10.1210/en.2003-1274
Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA), Journal of Bone and Mineral Metabolism, vol.43, issue.4, pp.274-282, 2006. ,
DOI : 10.4049/jimmunol.168.11.5824
Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients, Rheumatology, vol.45, issue.12, pp.451573-1575, 2006. ,
DOI : 10.1093/rheumatology/kel365
Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice, Modern Rheumatology, vol.8, issue.4, pp.306-310, 2007. ,
DOI : 10.1002/1529-0131(200111)44:11<2512::AID-ART431>3.0.CO;2-O
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis, J Clin Invest, vol.116, issue.10, pp.2633-2642, 2006. ,
Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo, Blood, vol.104, issue.4, pp.1094-1099, 2004. ,
DOI : 10.1182/blood-2003-12-4266
The kinase inhibitor imatinib mesylate inhibits TNF-alpha production in vitro and prevents TNF-dependent acute hepatic inflammation, Proc Natl Acad Sci, issue.38, pp.10213622-13627, 2005. ,
Sunitinib: A newly approved small-molecule inhibitor of angiogenesis, Drugs of Today, vol.42, issue.6, pp.387-98, 1998. ,
DOI : 10.1358/dot.2006.42.6.985633
Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cellmediated immune response in mice, Clinical immunology, issue.1, pp.135-55, 2010. ,
Inhibitory effects of sunitinib on ovalbumin-induced chronic experimental asthma in mice, Chin Med J (Engl), vol.122, issue.9, pp.1061-1066, 2009. ,
Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes, Clinical Science, vol.115, issue.4, pp.241-248, 1979. ,
DOI : 10.1016/j.cellsig.2006.02.012
Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: Comparison with vascular endothelial growth factor, tumor necrosis factor ?, and interleukin-1?-mediated breakdown, Journal of Neuroscience Research, vol.49, issue.3, pp.268-80, 1997. ,
DOI : 10.1002/(SICI)1097-4547(19970801)49:3<268::AID-JNR2>3.0.CO;2-A
Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood???retinal and blood???aqueous barrier breakdown, Experimental Eye Research, vol.80, issue.2, pp.249-58, 2005. ,
DOI : 10.1016/j.exer.2004.09.013
Vascular endothelial growth factor inhibition in uveitis: a systematic review, British Journal of Ophthalmology, vol.95, issue.2, pp.162-167, 2011. ,
DOI : 10.1136/bjo.2009.177279
Vascular endothelial growth factor gene polymorphisms and serum levels in Beh??et???s disease, Tissue Antigens, vol.30, issue.6, pp.581-588, 2009. ,
DOI : 10.1042/cs0940395
Activation of nuclear factor-kappa B in the conjunctiva with the epithelial scraping of the mouse cornea and human epidemic keratoconjunctivitis, British Journal of Ophthalmology, vol.88, issue.7, pp.88947-949, 2004. ,
DOI : 10.1136/bjo.2003.024646
Bortezomib attenuates murine collagen-induced arthritis, Annals of the Rheumatic Diseases, vol.68, issue.11, pp.681761-681768, 2009. ,
DOI : 10.1136/ard.2008.097709
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines, Blood, vol.107, issue.9, pp.3575-3583, 2006. ,
DOI : 10.1182/blood-2005-05-2118
Therapeutic potential of inhibition of the NF-??B pathway in the treatment of inflammation and cancer, Journal of Clinical Investigation, vol.107, issue.2, pp.135-142, 2001. ,
DOI : 10.1172/JCI11914
Proteasome inhibition: a new anti-inflammatory strategy, Journal of Molecular Medicine, vol.6, issue.4, pp.235-245, 2003. ,
DOI : 10.1016/S1074-5521(99)80128-8
Amelioration of Experimental Autoimmune Uveoretinitis with Nuclear Factor-??B Inhibitor Dehydroxy Methyl Epoxyquinomicin in Mice, Investigative Opthalmology & Visual Science, vol.51, issue.4, pp.2077-2084, 2010. ,
DOI : 10.1167/iovs.09-4030
Role of oxygen free radicals in retinal damage associated with experimental uveitis, Trans Am Ophthalmol Soc, vol.88, pp.797-850, 1990. ,
Peroxynitrite and oxidative damage in experimental autoimmune uveitis, Invest Ophthalmol Vis Sci, vol.38, issue.7, pp.1333-1339, 1997. ,
Pharmacological consequences of oxidative stress in ocular tissues, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol.579, issue.1-2, pp.22-36, 2005. ,
DOI : 10.1016/j.mrfmmm.2005.03.025
Decreased Total Antioxidant Response and Increased Oxidative Stress in Behcet's Disease, The Tohoku Journal of Experimental Medicine, vol.212, issue.2, pp.133-141, 2007. ,
DOI : 10.1620/tjem.212.133
Remission of diabetes while on sunitinib treatment for renal cell carcinoma, Annals of Oncology, vol.19, issue.4, pp.824-825, 2008. ,
DOI : 10.1093/annonc/mdn047
DRABICK : Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice, J Oncol Pharm Pract, 2010. ,
Inhibition of Th17 Cells Regulates Autoimmune Diabetes in NOD Mice, Diabetes, vol.58, issue.6, pp.1302-1311, 2009. ,
DOI : 10.2337/db08-1113
Monocytes from Patients with Type 1 Diabetes Spontaneously Secrete Proinflammatory Cytokines Inducing Th17 Cells, The Journal of Immunology, vol.183, issue.7, pp.4432-4439, 2009. ,
DOI : 10.4049/jimmunol.0900576
IL-17 Immunity in Human Type 1 Diabetes, The Journal of Immunology, vol.185, issue.3, pp.1959-1967, 2010. ,
DOI : 10.4049/jimmunol.1000788
Interphotoreceptor Retinoid-Binding Protein-Specific T Cells in Experimental Autoimmune Uveitis, Investigative Opthalmology & Visual Science, vol.48, issue.9, pp.4153-4161, 2007. ,
DOI : 10.1167/iovs.07-0251
VINORES : Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation, Molecular vision, vol.17, pp.492-507, 2011. ,
Vascular endothelial growth factor in eye disease, Progress in Retinal and Eye Research, vol.27, issue.4, pp.331-371, 2008. ,
DOI : 10.1016/j.preteyeres.2008.05.001
Experimental Diabetes Causes Breakdown of the Blood-Retina Barrier by a Mechanism Involving Tyrosine Nitration and Increases in Expression of Vascular Endothelial Growth Factor and Urokinase Plasminogen Activator Receptor, The American Journal of Pathology, vol.162, issue.6, pp.1995-2004, 2003. ,
DOI : 10.1016/S0002-9440(10)64332-5
Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behcet's syndrome, International journal of dermatology, issue.11, pp.42870-42875, 2004. ,
Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema, American Journal of Ophthalmology, vol.132, issue.5, pp.794-800, 2001. ,
DOI : 10.1016/S0002-9394(01)01103-5
Vascular endothelial growth factor (vegf) receptor-2 antagonists inhibit vegf-and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro, J Pharmacol Exp Ther, issue.3, pp.2991073-1085, 2001. ,
Decursin Inhibits VEGF-Mediated Inner Blood???Retinal Barrier Breakdown by Suppression of VEGFR-2 Activation, Journal of Cerebral Blood Flow & Metabolism, vol.39, issue.9, pp.1559-67, 2009. ,
DOI : 10.1016/S0014-4835(05)80048-X
Role of oxygen free radicals in retinal damage associated with experimental uveitis, Trans Am Ophthalmol Soc, vol.88, pp.797-850, 1990. ,
The Role of Nitric Oxide in Uveitis, Archives of Ophthalmology, vol.112, issue.4, pp.544-546, 1994. ,
DOI : 10.1001/archopht.1994.01090160124032
Retinal Vascular Endothelial Growth Factor Induces Intercellular Adhesion Molecule-1 and Endothelial Nitric Oxide Synthase Expression and Initiates Early Diabetic Retinal Leukocyte Adhesion in Vivo, The American Journal of Pathology, vol.160, issue.2, pp.501-509, 2002. ,
DOI : 10.1016/S0002-9440(10)64869-9
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients, Clinical Cancer Research, vol.14, issue.20, pp.146674-6682, 2008. ,
DOI : 10.1158/1078-0432.CCR-07-5212
T helper cell subsets in insulin-dependent diabetes, Science, vol.268, issue.5214, pp.1185-1188, 1995. ,
DOI : 10.1126/science.7761837
SARVETNICK : Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes, J Immunol, vol.162, issue.5, pp.2511-2520, 1999. ,
Th1-like dominance in high-risk first-degree relatives of Type I diabetic patients, Diabetologia, vol.43, issue.6, pp.742-749, 2000. ,
DOI : 10.1007/s001250051372
Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health, Journal of Clinical Investigation, vol.113, issue.3, pp.451-463, 2004. ,
DOI : 10.1172/JCI19585
Immunopathogenic role of TH1 cells in autoimmune diabetes: Evidence from a T1 and T2 doubly transgenic non-obese diabetic mouse model, Journal of Autoimmunity, vol.25, issue.3, pp.181-192, 2005. ,
DOI : 10.1016/j.jaut.2005.08.010
Effector Function of Diabetogenic CD4 Th1 T Cell Clones: A Central Role for TNF-??, The Journal of Immunology, vol.175, issue.11, pp.7738-7745, 2005. ,
DOI : 10.4049/jimmunol.175.11.7738
The pattern of inflammatory/anti-inflammatory cytokines and chemokines in type 1 diabetic patients over time, Annals of Medicine, vol.76, issue.6, pp.426-438, 2010. ,
DOI : 10.1016/j.jbspin.2008.08.002
Understanding Autoimmune Uveitis through Animal Models The Friedenwald Lecture, Investigative Opthalmology & Visual Science, vol.52, issue.3, pp.1872-1879, 2011. ,
DOI : 10.1167/iovs.10-6909
LEE : Imbalance of Th17 to Th1 cells in Beh cet's disease, Clin Exp Rheumatol, vol.28, issue.4, pp.16-19, 2010. ,
BROSSART : Sorafenib, but not sunitinib , affects function of dendritic cells and induction of primary immune responses, Blood, issue.12, pp.1115610-5620, 2008. ,
VERHEUL : Anti-angiogenic tyrosine kinase inhibitors : what is their mechanism of action ? Angiogenesis, pp.1-14 ,